Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Trump, Xi set for Beijing talks with trade truce, Iran war at stake

Published

on

Trump, Xi set for Beijing talks with trade truce, Iran war at stake
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

(VIDEO) Victor Wembanyama Embraces Villain Role in New York as Spurs Stun Knicks in Game 3 of 2026 NBA Finals

Published

on

Victor Wembanyama

NEW YORK — Victor Wembanyama delivered a dominant performance with 32 points, eight rebounds, six assists and three blocks as the San Antonio Spurs defeated the New York Knicks 115-111 in Game 3 of the 2026 NBA Finals on Monday night at Madison Square Garden, cutting the Knicks’ series lead to 2-1 and embracing his status as the city’s newest villain.

The 7-foot-4 French phenom, in his third NBA season, led the Spurs to their first road victory in the Finals since 1999, snapping a lengthy drought at the world’s most famous arena. Stephon Castle came off the bench with 23 points, providing crucial scoring as the Spurs overcame early deficits and capitalized on Knicks turnovers.

Wembanyama addressed the hostile environment and his growing reputation among Knicks fans in a postgame interview. He acknowledged the “villain” label with characteristic humor and humility, noting he still falls short of past antagonists like Trae Young.

Advertisement

“I guess I’m nowhere near Trae Young’s level though,” Wembanyama said when asked about becoming New York’s latest villain.

The comment reflected the intensity of the series, which has featured physical play, star matchups and off-court drama including high-profile attendees like former President Donald Trump at Game 3. Knicks fans have directed significant energy toward the Spurs’ young superstar, who has quickly become a focal point of their frustrations.

Despite the boos, Wembanyama thrived in the spotlight. His scoring outburst included efficient shooting and playmaking that stretched the Knicks’ defense. The Spurs mounted a strong second-half surge, overcoming 13 Knicks turnovers and navigating lopsided free-throw disparities in the latter stages.

Jalen Brunson led the Knicks with 32 points, but New York struggled with ball security and late execution. Coach Tom Thibodeau and players expressed frustration with officiating, particularly after halftime when the Spurs received 24 free throws to the Knicks’ eight.

Advertisement

The victory marked a critical response for the Spurs after dropping the first two games in San Antonio. Wembanyama, who had shouldered much of the blame for costly late mistakes in Game 2, channeled that disappointment into a focused effort. Earlier in the series, he had admitted to moments of overexcitement following the Western Conference Finals triumph over Oklahoma City.

“This is what I’m built for,” Wembanyama said in the lead-up to Game 3, expressing confidence in his ability to help the Spurs mount a comeback.

The 22-year-old’s poise under pressure has been a hallmark of his rapid rise. Selected first overall in 2023, Wembanyama has transformed the Spurs into contenders faster than many anticipated. His unique combination of size, skill and basketball IQ continued to shine in the Finals spotlight.

Game 3 featured the familiar electric atmosphere of Madison Square Garden during playoff runs. Celebrities and notable figures packed the arena, adding to the spectacle. The crowd’s energy intensified whenever Wembanyama touched the ball, a dynamic he appeared to relish rather than shrink from.

Advertisement

Spurs coach Gregg Popovich, known for his strategic acumen, adjusted schemes to maximize Wembanyama’s versatility. The big man’s ability to guard multiple positions while dominating offensively has been pivotal. Defensively, he continued to alter shots and protect the rim, though the Knicks’ spacing tested those strengths.

For the Knicks, the loss at home stung after building a 2-0 advantage. Brunson and teammates will need to regroup quickly for Game 4 on Thursday, also at the Garden. The series has highlighted the physical toll of Finals basketball, with both teams showing resilience amid the physicality.

Wembanyama’s emergence as a villain echoes past playoff narratives in New York, where opposing stars often face intense scrutiny. His calm demeanor off the court contrasts with his on-court dominance, making him a compelling figure in the league’s premier stage.

Beyond the individual performances, the game underscored broader themes in the 2026 Finals. The Spurs represent a youthful, restructured roster built around Wembanyama, while the Knicks rely on veteran leadership and home-court passion. Game 3 shifted momentum, setting up a potentially extended series.

Advertisement

Analysts noted the Spurs’ bench contributions and defensive adjustments as key factors. Castle’s scoring provided a spark, while the team’s ability to force turnovers disrupted the Knicks’ rhythm. Free-throw disparities fueled postgame discussions, with Knicks coach Mike Brown voicing strong opinions on the officiating.

Wembanyama has spoken previously about embracing challenges and the journey of competition. His focus remains on the collective goal rather than personal accolades. The Spurs’ resilience after an 0-2 start demonstrates the mental toughness Popovich has instilled in the group.

As the series returns to Madison Square Garden for Game 4, anticipation builds for another intense matchup. Knicks fans will look to reclaim home dominance, while Spurs supporters and neutral observers watch to see if Wembanyama can sustain his elevated play amid the villain narrative.

The 2026 NBA Finals have captivated audiences with star power, drama and competitive balance. Wembanyama’s postgame comments and performance added another layer to the storyline, reinforcing his status as one of the league’s most intriguing talents. Whether the Spurs can force a longer series depends on their continued execution against a resilient Knicks team.

Advertisement

League officials and fans alike recognize the value of such rivalries in elevating the sport. For Wembanyama, playing the antagonist role in New York appears to fuel rather than distract from his mission. With the series far from decided, both teams prepare for what promises to be another memorable chapter.

Continue Reading

Business

nVent Electric: A High Quality Electrification Story Than The Market Realizes (NYSE:NVT)

Published

on

nVent Electric: A High Quality Electrification Story Than The Market Realizes (NYSE:NVT)

This article was written by

My background is in Financial Engineering and I have long since been interested in analyzing strong solid companies with a rare financial Profile. My primary area of specialization is in quantamental analysis, where I use a combination of data driven models and fundamental research. My approach is centered on a structured process that combines top-down screening with bottom-up company specific analysis .I write on to share ideas with a wider audience and also learn more about companies and other analysts. My goal is to make unique ideas & research accessible to retail and professional investors alike, while maintaining analytical depth and a clear investment thesis.Associated with another author Kennedy Njagi

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NVT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Dow Jones Surges Nearly 390 Points as Markets Rebound on AI Optimism and Easing Geopolitical Tensions

Published

on

FTSE 100 Surges 0.8% Today as Oil Eases and Markets

NEW YORK — The Dow Jones Industrial Average climbed 389.58 points to close at 51,175.59 on Tuesday, marking a strong rebound as investors embraced renewed enthusiasm for artificial intelligence-related stocks and signs of potential de-escalation in Middle East tensions, helping lift broader market sentiment amid ongoing economic uncertainties.

The blue-chip index’s gain reflected a broader recovery across equities after recent volatility driven by geopolitical risks and sector rotations. Technology and semiconductor shares led advances, with several Dow components posting solid gains as traders bet on continued capital spending in AI infrastructure despite fluctuating energy prices and upcoming inflation data.

Market participants welcomed comments from President Donald Trump suggesting progress in peace talks involving Iran, which helped ease concerns over oil supply disruptions. Oil prices moderated, providing relief to transportation and industrial stocks within the Dow. The rebound followed a mixed session the previous day, where the index had closed lower amid choppy trading.

Analysts noted the Dow’s move toward the 51,000 level underscores resilience in the U.S. economy even as investors monitor Federal Reserve policy signals and corporate earnings. With the index having flirted with record territory in recent weeks, Tuesday’s advance highlighted underlying strength in cyclical sectors and Big Tech’s enduring influence on market direction.

Advertisement

The S&P 500 and Nasdaq Composite also posted gains, with the tech-heavy Nasdaq benefiting from rebounds in chipmakers and data center plays. Broader participation included advances in financials and consumer discretionary names, suggesting improving risk appetite as traders looked past short-term noise.

Key drivers included optimism around AI infrastructure spending. Companies tied to data centers and semiconductors extended recoveries from earlier sell-offs, with investors citing strong demand fundamentals from hyperscalers and enterprise clients. China’s reported plans for significant data center investments over the coming years further supported the narrative of sustained global AI growth.

Geopolitical developments played a supporting role. Reduced immediate fears of escalation in the Middle East helped stabilize energy markets, with oil prices easing from recent spikes. This dynamic benefited Dow components sensitive to fuel costs, including industrials and airlines.

Economists and strategists remain focused on upcoming inflation readings and Federal Reserve communications. While rate cut expectations have shifted, resilient corporate earnings and productivity gains tied to technology adoption continue to underpin equity valuations. The Dow’s year-to-date performance reflects a market that has absorbed multiple headwinds while climbing to new highs.

Advertisement

Blue-chip performers on Tuesday included names with exposure to AI and enterprise technology, alongside traditional industrials benefiting from lower energy costs. Conversely, some defensive sectors lagged as investors rotated toward growth opportunities. Volume remained healthy, indicating genuine conviction in the rebound rather than purely technical buying.

Looking ahead, market watchers will scrutinize Wednesday’s consumer price index data for clues on inflation trajectory. Any signs of cooling could reinforce hopes for monetary policy flexibility later in the year, while hotter-than-expected figures might temper enthusiasm. Corporate earnings season also continues, with major reports providing further insight into business conditions.

The Dow’s composition of 30 large, established companies makes its movements particularly noteworthy for retail investors and as a barometer of economic health. Recent gains have pushed the index well above levels seen earlier in the year, with contributions from both legacy industrials and newer technology-weighted members.

Broader context includes solid first-quarter earnings beats across much of the S&P 500, with operating margins holding near record levels. AI-related capital expenditure remains a dominant theme, supporting valuations even at elevated multiples. However, risks persist, including potential policy shifts, geopolitical flare-ups and consumer spending patterns amid mixed economic signals.

Advertisement

International markets showed mixed performance, with Asian indices rebounding on AI optimism and European bourses reflecting regional economic data. Currency movements, particularly in the dollar, influenced multinational Dow components. Bond yields remained in focus as investors balanced growth optimism with rate expectations.

For individual investors, Tuesday’s action reinforces the importance of diversification and long-term perspective. While the Dow’s advance is encouraging, volatility remains inherent in equity markets. Financial advisers recommend focusing on fundamentals, company-specific developments and portfolio alignment with risk tolerance rather than short-term swings.

Sector rotation continues to define the 2026 market environment. Technology and communication services have driven much of the year’s gains, but industrials, financials and energy have shown periodic strength as the economy demonstrates resilience. The Dow’s price-weighted nature means higher-priced stocks exert outsized influence, making moves in components like UnitedHealth, Goldman Sachs and Caterpillar particularly impactful.

As the trading session concluded, futures pointed to continued cautious optimism overnight. Market breadth improved, with advancing issues outnumbering decliners on major exchanges. This technical improvement could support further upside if upcoming data remains constructive.

Advertisement

The Dow’s climb to the 51,000 level marks another psychological milestone in a bull market that has defied numerous challenges. From inflation concerns to geopolitical risks, equities have demonstrated remarkable durability, underpinned by corporate innovation and earnings growth. Whether this momentum sustains depends on the interplay of policy, profits and global developments in the weeks ahead.

Investors will continue monitoring Federal Reserve officials’ comments and key economic releases for direction. In the meantime, Tuesday’s solid gain provides a positive note as markets navigate the balance between enthusiasm for transformative technologies and traditional economic realities.

Continue Reading

Business

American Eagle declares $0.125 quarterly dividend

Published

on


American Eagle declares $0.125 quarterly dividend

Continue Reading

Business

Zealand Pharma A/S (ZLDPY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Zealand Pharma A/S (ZLDPY) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:20 PM EDT

Company Participants

Adam Steensberg – President & CEO

Conference Call Participants

Advertisement

Rajan Sharma – Goldman Sachs Group, Inc., Research Division

Presentation

Rajan Sharma
Goldman Sachs Group, Inc., Research Division

Advertisement

Good afternoon, everyone. Thanks for joining us. My name is Rajan Sharma, European pharma and biotech analyst here at Goldman Sachs. Very pleased to have Zealand Pharma with us and Adam Steensberg, CEO. Adam, thank you. Thanks for joining. I know that you’ve been on the road with ADA. So thanks for adding on this to the trip.

Adam Steensberg
President & CEO

Pleased to be here.

Advertisement

Question-and-Answer Session

Rajan Sharma
Goldman Sachs Group, Inc., Research Division

Advertisement

Lots to get through. And obviously, we’re coming off the back of ADA. So maybe that’s a good place to start. There are a few updates there, both with survodutide and petrelintide. Could you maybe just start with survodutide because that was kind of the more — or the newer update that we got over the weekend and just provide your thoughts on the data.

Adam Steensberg
President & CEO

Absolutely. And as you said, I just went almost a week around at ADA, and it was really, you can say, positive experience coming out of ADA, kicking off Friday with a symposium on amylin and really starting to change the conversations from how we get to the maximum tolerated doses more towards how do you get to the minimum effective doses when you think about treating obesity.

Advertisement

So there’s a quite significant change in the ecosystem right now that we start to see more modalities approaching the market and specifically with Boehringer being the CEO, Sid, and I was, of course, extremely pleased to see the strong presence they

Advertisement
Continue Reading

Business

Nasdaq Climbs 1.27% on AI Rebound as Tech Stocks Lead Market Recovery

Published

on

The tech sector led record gains in the S&P 500 index. Pictured: a man with umbrella walks past the New York Stock Exchange.

NEW YORK — The Nasdaq Composite rose 329.42 points, or 1.27%, to close at 26,259.09 on Tuesday, driven by renewed investor enthusiasm for artificial intelligence-related shares and a broader market rebound amid easing geopolitical concerns and optimism over technology infrastructure spending.

The tech-heavy index snapped back from recent volatility as semiconductor and data center stocks extended gains for a second straight session. Chipmakers and related names benefited from continued focus on AI buildout, with investors rotating back into growth-oriented technology plays after a period of profit-taking and sector rotation.

The advance came as U.S. stock futures had pointed higher overnight, with the AI trade taking center stage once again. Contracts tied to the Nasdaq 100 rose notably in pre-market trading, setting the tone for a positive session across major averages. The S&P 500 and Dow Jones Industrial Average also posted gains, though the Nasdaq outperformed on the strength of its heavy technology weighting.

Analysts attributed the move to sustained demand expectations for AI infrastructure. Companies involved in chips, memory, storage and data centers led the charge, reflecting ongoing capital expenditure commitments from major cloud providers and hyperscalers. Recent developments, including new filings and investments in the AI ecosystem, reinforced confidence in long-term growth prospects for the sector.

Advertisement

Geopolitical factors provided additional support. Reduced immediate fears of escalation in the Middle East helped stabilize energy markets, easing pressure on broader equities and allowing investors to focus on corporate fundamentals and innovation themes. Oil prices moderated, benefiting sectors sensitive to input costs while freeing capital flows back into risk assets.

The session highlighted the Nasdaq’s sensitivity to technology momentum. With the index heavily influenced by a relatively small number of mega-cap names, gains in key constituents amplified the overall performance. Broader participation improved as well, with many mid-cap tech and growth stocks joining the rally.

Market breadth was constructive, with advancing issues outpacing decliners on the Nasdaq. Volume remained solid, suggesting genuine conviction rather than purely technical buying. This rebound followed a mixed period where concerns over valuations, interest rates and short-term economic data had weighed on sentiment.

Looking ahead, investors will closely monitor upcoming inflation data, including the consumer price index release, for signals on the Federal Reserve’s policy path. While rate cut expectations have been tempered, resilient corporate earnings and productivity gains from technology adoption continue to support higher valuations in growth sectors.

Advertisement

The AI theme remains dominant in 2026 market narratives. Companies positioned across the supply chain — from chips and servers to software and applications — have seen substantial investor interest. Optimism around new product launches, partnerships and infrastructure expansions has repeatedly fueled rallies even amid periodic pullbacks.

Broader economic context includes solid corporate results in recent quarters, with many technology firms exceeding expectations on AI-related revenue. Margins have held firm, and forward guidance has generally reinforced investment cycles. However, risks such as potential policy shifts, regulatory scrutiny and cyclical slowdowns in certain end markets persist.

International developments also factored into Tuesday’s trading. Asian markets showed mixed performance overnight, while European bourses reflected regional data and corporate news. Currency fluctuations, particularly involving the U.S. dollar, influenced multinational technology companies with significant overseas exposure.

For individual investors, the Nasdaq’s movement underscores the importance of diversification within growth portfolios. While technology has driven much of the market’s upside in recent years, concentration risks remain a key consideration. Financial advisers recommend balancing exposure with traditional sectors and maintaining long-term horizons amid volatility.

Advertisement

The index’s year-to-date performance reflects resilience despite multiple headwinds. From earlier concerns over inflation and rates to periodic geopolitical flares, the Nasdaq has demonstrated durability underpinned by innovation and earnings power. Tuesday’s gain pushed it closer to recent highs, with technical indicators showing potential for continuation if upcoming catalysts remain positive.

Sector rotation dynamics continue to shape trading patterns. After periods of dominance by mega-cap technology, money has periodically flowed into value, small-caps and other areas. However, AI tailwinds have repeatedly drawn capital back to growth names, creating a supportive environment for the Nasdaq.

Corporate news flow supported sentiment. Developments around major players in chips, cloud computing and software contributed to positive momentum. Analysts expect this focus to persist as companies report quarterly results and provide updates on AI initiatives throughout the earnings season.

Bond markets offered a mixed backdrop, with Treasury yields moving in response to growth optimism and rate expectations. The dollar’s performance influenced export-oriented tech firms. Commodity prices, including metals relevant to technology manufacturing, also factored into sector performance.

Advertisement

As trading concluded, futures pointed to continued monitoring overnight. Market participants will digest economic releases and corporate updates in the days ahead. The balance between enthusiasm for transformative technologies and traditional valuation discipline will likely remain central to near-term direction.

The Nasdaq’s role as a barometer for innovation and risk appetite makes its movements particularly noteworthy. Tuesday’s solid advance provides a positive note as markets navigate the intersection of artificial intelligence potential and macroeconomic realities. Whether momentum builds further depends on data, earnings and global developments in the weeks ahead.

Continue Reading

Business

GSK Agrees to Acquire Nuvalent for $10.6 Billion in Major Oncology Deal, Sending Shares Soaring 39%

Published

on

Moderna MRNA Stock 2026 Outlook: Buy or Sell the mRNA

NEW YORK — Nuvalent Inc. shares skyrocketed more than 38% in early trading Tuesday after British pharmaceutical giant GSK announced a $10.6 billion all-cash agreement to acquire the Boston-based clinical-stage biotechnology company focused on precision oncology therapies for lung cancer.

Nuvalent stock jumped to around $122.87, up $34.38 or 38.85% from Monday’s close, trading near the $124 per share offer price as investors reacted to the significant premium. The deal values the company at an equity total of approximately $10.6 billion, or $9.4 billion net of cash, representing a 40% premium to the prior closing price and a 26% premium to the 30-day volume-weighted average price.

Under the terms, GSK will commence a tender offer to acquire all outstanding shares of Nuvalent’s Class A and Class B common stock at $124 per share in cash. The transaction is expected to close in the second half of 2026, subject to customary conditions including regulatory approvals and the tender of a majority of shares.

The acquisition bolsters GSK’s oncology portfolio with Nuvalent’s promising pipeline of targeted therapies for ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Nuvalent’s lead candidates, zidesamtinib and neladalkib, have shown strong clinical activity in heavily pretreated patients, including those with brain metastases and resistance mutations, addressing key limitations of existing treatments.

Advertisement

GSK highlighted the strategic fit, noting Nuvalent’s focus on validated targets with potential to overcome efficacy and tolerability issues in current standards of care. The deal includes multiple assets in lung cancer, a high-priority area for the British drugmaker as it seeks to strengthen its innovative medicines pipeline.

Nuvalent, founded in 2017, specializes in developing small-molecule inhibitors designed for precision targeting of kinase-driven cancers. Its candidates aim to provide better brain penetration and selectivity compared to earlier-generation therapies, potentially improving outcomes for patients with advanced disease. Positive pivotal data from trials like ALKOVE-1 and ARROS-1 had already positioned the company as an attractive player in the competitive oncology space.

The announcement marks one of the largest biotechnology acquisitions of 2026, underscoring continued big pharma interest in late-stage oncology assets amid patent cliffs and the need for innovative pipelines. For Nuvalent shareholders, the premium represents substantial value realization after years of clinical development.

Company executives expressed enthusiasm about the combination. The deal allows Nuvalent’s science to advance under GSK’s global resources while delivering immediate and attractive returns to investors. GSK reiterated its commitment to its dividend policy and 2026 guidance despite the investment.

Advertisement

Wall Street analysts had been bullish on Nuvalent prior to the news, with consensus price targets well above previous trading levels citing its differentiated pipeline and potential for multiple approvals. The GSK offer exceeds many of those targets, validating the company’s progress in precision oncology.

The surge in trading volume reflected widespread investor excitement, with shares hitting new record highs intraday. Market watchers noted the deal’s structure as a clean all-cash tender, reducing uncertainty and providing a clear path to completion. Regulatory reviews are anticipated to focus on antitrust considerations in the oncology sector, though the targeted nature of the assets may limit concerns.

For the broader biotechnology sector, such transactions highlight the value of innovative clinical assets in a challenging funding environment. Nuvalent’s success in advancing candidates to late-stage development and regulatory submissions has made it an appealing target for larger players seeking near-term revenue drivers.

GSK’s move aligns with industry trends of consolidation in oncology, where large companies leverage acquisitions to complement internal research and accelerate growth. The British firm has been active in dealmaking to rebuild its pipeline following several patent expirations.

Advertisement

Nuvalent’s pipeline includes zidesamtinib for ROS1-positive NSCLC and neladalkib for ALK-positive disease, both with encouraging data in pretreated populations and potential in frontline settings. Positive results presented at major medical meetings had de-risked the programs and attracted significant attention.

The acquisition is expected to have minimal immediate impact on GSK’s 2026 financial guidance. The company emphasized that the transaction supports its long-term strategy without compromising shareholder returns through dividends.

Biotechnology investors often view such deals as validation of platform technologies and clinical execution. For Nuvalent, which went public in 2021, the agreement caps a rapid ascent from early research to a multibillion-dollar exit. The premium rewards patience from long-term holders and early backers.

As the tender offer process begins, shareholders will evaluate the offer against any potential superior proposals, though the substantial premium and strategic fit make competing bids less likely. The deal is structured to close efficiently once conditions are satisfied.

Advertisement

The news provides a positive backdrop for the broader biotech sector, where M&A activity has been a key driver amid volatile public markets. Companies with strong clinical data in high-unmet-need areas continue to attract interest from strategic buyers.

Nuvalent will continue operations as usual pending closing, with ongoing clinical trials and regulatory activities advancing. The combination is expected to accelerate development and commercialization of its therapies on a global scale under GSK’s infrastructure.

Market reaction extended beyond Nuvalent, with modest gains in other precision oncology names as investors assessed potential ripple effects. The deal reinforces confidence in the long-term value of targeted cancer therapies despite periodic sector volatility.

As details emerge in the coming days, attention will turn to integration plans, regulatory timelines and potential synergies. For now, the announcement delivers significant value to Nuvalent shareholders while positioning GSK to strengthen its presence in lung cancer treatments.

Advertisement
Continue Reading

Business

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Published

on

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Incyte INCY -1.70%decrease; red down pointing triangle has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company’s hematology portfolio into bleeding disorders.

Incyte on Monday said it will pay an initial $1.25 billion in cash to acquire Vega from privately held Star Therapeutics, which will be eligible to receive up to $750 million in additional payments based on sales milestones.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Business

Police Name Suspect in Separate Kidnapping Near Nancy Guthrie’s Arizona Home

Published

on

Savannah Guthrie & Nancy Guthrie

TUCSON, Ariz. — Authorities in Pima County have identified a suspect in a separate kidnapping case that occurred just miles from the home of missing 84-year-old Nancy Guthrie, even as the high-profile investigation into her February abduction remains active with no direct link established between the cases.

The Pima County Sheriff’s Department on Monday named 40-year-old Coral Michelle Smith as wanted in connection with a kidnapping and aggravated assault with a deadly weapon that took place on May 29, roughly seven miles from Guthrie’s residence in the Catalina Foothills area. Smith faces charges stemming from that incident, according to officials and local reports.

Smith, who also uses aliases including Corral Albright, Coral Albright-Smith and Under The Sea Smith, is described as 5 feet 6 inches tall, weighing approximately 136 pounds, with blonde hair and blue eyes. She has several tattoos, though none on her wrist, authorities noted. A $1,000 reward is being offered for information leading to her arrest.

The development comes more than four months after Guthrie was reported missing on Feb. 1. Investigators believe she was abducted from her home in the early morning hours, citing evidence such as her pacemaker data, doorbell camera footage showing a masked figure and other forensic indicators at the scene. No arrests have been made in her case, and officials continue to treat it as an active abduction investigation.

Advertisement

Pima County authorities have stressed that there is currently no believed connection between Smith and Guthrie’s disappearance. The separate case highlights ongoing public safety concerns in the Tucson area, where law enforcement has urged residents to remain vigilant while pursuing multiple leads across investigations.

Smith has an extensive criminal history that includes prior arrests for robbery, disorderly conduct, aggravated assault and another kidnapping incident, according to court records and local reporting. Anyone who sees her is urged to call 911 immediately or provide anonymous tips to Tucson’s 88-Crime hotline at 1-520-882-7463.

The Guthrie family, led by her daughter Savannah Guthrie, the co-anchor of NBC’s “Today” show, continues to appeal for public assistance. A substantial reward totaling more than $1.2 million, including contributions from the family and federal authorities, remains available for information leading to Nancy Guthrie’s safe return. Tips can be submitted to the FBI at 1-800-CALL-FBI or the Pima County Sheriff’s Department.

Savannah Guthrie has been vocal in recent weeks about the emotional toll, sharing public messages of hope while balancing her professional responsibilities. In a recent Instagram Story, she wrote, “Oh my, my soul it cries out, soul, it cries out,” while urging whoever took her mother to “bring her home.”

Advertisement

Retired FBI agent Jason Pack, in a June 2026 interview with Parade, suggested that pressure in the Guthrie case may eventually lead to a breakthrough. “Four months is a long time to keep a secret, and people start to crack,” Pack said. “They make calls they shouldn’t make. They spend money they can’t explain. They act nervous when there’s no reason to be nervous.”

Pack added that the large reward adds compounding pressure. “The $1 million reward is still on the table, and that kind of pressure doesn’t expire. It compounds. Somebody knows something, and the weight of that is getting heavier every single day.”

The investigation into Guthrie’s disappearance has involved extensive resources from the Pima County Sheriff’s Department and the FBI, including analysis of DNA evidence, review of thousands of tips and coordination with federal partners. Physical evidence at the home, including reports of blood at the scene, has pointed toward a violent abduction rather than a voluntary departure.

Community members in the Tucson area have expressed concern over the separate kidnapping case involving Smith, particularly given its proximity to the Guthrie residence. Local media have reported increased attention to neighborhood security and awareness in the affluent Catalina Foothills neighborhood.

Advertisement

Authorities have not released additional details about the May 29 incident involving Smith, citing the ongoing nature of that investigation. The timing, however, has drawn public interest as both cases unfold in the same region.

For the Guthrie family, the prolonged uncertainty has been particularly difficult. Nancy Guthrie, a mother of three, was last seen the evening of Jan. 31 after spending time with family. Her pacemaker reportedly disconnected around 2:28 a.m. on Feb. 1, helping establish the timeline. Doorstep camera footage captured a masked individual, adding to the mystery surrounding her whereabouts.

Savannah Guthrie temporarily stepped away from her anchoring duties earlier this year to focus on the search and family matters before returning in April. She has spoken candidly about balancing grief with daily responsibilities, including protecting her two young children while maintaining hope for her mother’s return.

The dual investigations underscore challenges faced by law enforcement in high-profile missing persons cases. While the Guthrie case has captured national attention due to her daughter’s prominence, the separate incident involving Smith serves as a reminder of broader regional safety issues that require sustained vigilance.

Advertisement

As both cases progress, officials continue to appeal for tips from the public. Even seemingly minor information could prove valuable. Forensic work, including advanced DNA analysis, remains ongoing in the Guthrie investigation, with hopes that technological advances or a key witness could provide a breakthrough.

The community and national audiences have followed developments closely, with vigils and support efforts continuing. The large reward in the Guthrie case has generated significant interest, though authorities caution that tips must be credible and actionable.

Law enforcement has not indicated any immediate timeline for resolution in either matter but emphasized dedication to thorough investigation. For the Guthrie family, each day without answers adds to the emotional weight, as Savannah Guthrie continues to publicly express her longing for her mother’s safe return.

Anyone with information on either case is strongly encouraged to contact the appropriate authorities. The Pima County Sheriff’s Department and FBI remain committed to pursuing all leads in these serious matters affecting the Tucson community.

Advertisement
Continue Reading

Business

Palantir: Even A Historic Quarter Could Not Move The Needle (NASDAQ:PLTR)

Published

on

The Market Is Offering Palantir Stock On A Golden Platter (NASDAQ:PLTR)

This article was written by

As a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons that could offer substantial returns. Energy Transfer is one of those companies that I came across when no one wanted to touch it and now I can’t resolve myself to sell it. I will always focus more on long-term value investing but I can sometimes lose myself in possible deal arbitrage such as with Microsoft/ Activision Blizzard, Spirit Airlines/Jetblue (that one still hurts), and Nippon/U.S. Steel (perfect exit at $50.19). I tend to shun businesses that I can’t understand either high-tech or certain consumer goods such as fashion (give me a Levi’s jeans). I don’t understand why anyone would invest in cryptocurrencies as well. Through Seeking Alpha, I aim to connect with like-minded investors, share insights, and build a collaborative community of individuals seeking superior returns and informed decision-making, currently on a quest to review every public company.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Trending

Copyright © 2025